Pasquale Striano

University of Genoa
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Background: Although home births provide personal and intimate experiences, they pose potential risks that may be better managed in hospital settings. The safety of home birth remains highly debated, with no consensus on its safety or potential adverse events, and its adoption varies widely across the world. In Italy, the Italian Society of Neonatology opposed this practice, resulting in one of the lowest home birth rates in Europe (approximately 0.1% of total births). This study evaluated the impact of planned home births on neonatal health, with a focus on severe complications requiring intervention in the pediatric emergency department (PED). Methods: Cases were collected from patients admitted to IRCCS Istituto Giannina Gaslini Children’s Hospital between January 2022 and December 2024. The analysis focused on neonates born at home, who required emergency care for life-threatening conditions. Results: We identified five cases, with an incidence of approximately 0.65 per 10,000 PED visits and a complication rate of 15–30% for all planned home births. Factors contributing to unfavorable outcomes include lack of advanced medical equipment, timely diagnostics, and comprehensive postpartum screening. Thus, while proponents argue that home births can provide a more comfortable and personalized experience, concerns about safety and associated risks persist. Conclusions: This study aims to highlight the necessity of adopting hospital-level neonatal care protocols for home births, particularly during the critical first 48 h of life, to mitigate risks and ensure optimal neonatal outcomes.

Year:

2025

Sunflower syndrome, a rare photosensitive epilepsy characterized by handwaving episodes and fixation on light sources, remains poorly understood, especially regarding its neuropsychological profile. This study provides a detailed cognitive evaluation of two patients, revealing a likely disruption in the visual dorsal stream, with particular involvement of the ventral attention network (VAN). Despite normal overall intellectual functioning, both patients exhibited significant deficits in Processing Speed Index and inhibitory control, indicating selective executive dysfunction. Coupled with EEG anomalies predominantly in the right frontal lobe, these findings suggest right hemisphere involvement, potentially along the VAN pathway. This study highlights the need for further research, particularly functional neuroimaging, to better understand the neurocognitive aspects of sunflower syndrome and its impact on patients' quality of life.

Year:

2025

A bstract Temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) is associated with a complex genetic architecture, but the translation from genetic risk factors to brain vulnerability remains unclear. Here, we examined associations between epilepsy-related polygenic risk scores for HS (PRS-HS) and brain structure in a large sample of neurotypical children, and correlated these signatures with case-control findings in in multicentric cohorts of patients with TLE-HS. Imaging-genetic analyses revealed PRS-related cortical thinning in temporo-parietal and fronto-central regions, strongly anchored to distinct functional and structural network epicentres. Compared to disease-related effects derived from epilepsy case-control cohorts, structural correlates of PRS-HS mirrored atrophy and epicentre patterns in patients with TLE-HS. By identifying a potential pathway between genetic vulnerability and disease mechanisms, our findings provide new insights into the genetic underpinnings of structural alterations in TLE-HS and highlight potential imaging-genetic biomarkers for early risk stratification and personalized interventions.

Year:

2025

(1) Background: The first 1000 days of life constitute a critical window of opportunity for microbiota development. Nutrients play a crucial role in enriching and diversifying the microbiota, derived not only from solid food but also from maternal dietary patterns during gestation. (2) Methods: We conducted a comprehensive literature review using the PubMed database, covering eleven years (2013–2023). We included English-language reviews, original research papers, and meta-analyses, while excluding case reports and letters. (3) Results: Consensus in the literature emphasizes that our interaction with a multitude of microorganisms begins in the intrauterine environment and continues throughout our lives. The existing data suggest that early nutritional education programs, initiated during pregnancy and guiding infant diets during development, may influence the shaping of the gut microbiota, promoting long-term health. (4) Conclusions: Further research is necessary in the coming years to assess potential interventions and early nutritional models aimed at modulating the pediatric microbiota, especially in vulnerable populations such as premature newborns.

Year:

2024

Objective This study was undertaken to characterize the clinical and genetic features of patients with 22q11.2 deletion syndrome (22q11.2DS) and generalized epilepsy compared with 22q11.2DS individuals without epilepsy. Methods This multicenter case–control study included 28 patients with 22q11.2DS‐related generalized epilepsy and compared their data with 56 age‐matched 22q11.2DS controls without epilepsy. Clinical and electroencephalographic features, neuropsychiatric and systemic comorbidities, family history of epilepsy, and genetic findings were collected. Results Generalized tonic–clonic seizures and myoclonic seizures were the most common electroclinical presentations, with a broader range of seizure type combinations also documented. Most patients achieved seizure remission with antiseizure medications, with only 4% exhibiting drug resistance. A higher prevalence of family history of epilepsy was observed among patients with 22q11.2DS‐related generalized epilepsy compared to nonepilepsy controls, even when limiting the analysis to patients with known de novo deletions. No differences in deletion size or location were observed between the groups. Multivariable logistic regression analysis identified family history of epilepsy, intellectual disability, and lack of skeletal abnormalities as independent factors associated with generalized epilepsy, whereas a history of psychosis was significant only in univariable analysis. Significance This study provides a detailed characterization of generalized epilepsy in individuals with 22q11.2DS and highlights specific associated comorbidities. The higher prevalence of family history of epilepsy among cases suggests that genetic factors beyond the 22q11.2 deletion influence the development of the epilepsy phenotype, providing new insights into the genetic underpinnings of phenotypic variability in this syndrome.

Year:

2024

Background: Human milk (HM) is recognized as an ideal source of nutrition for newborns; as a result, its multiple bioactive molecules can support the growth of healthy newborns and reduce the risk of mortality and diseases such as asthma, respiratory infections, diabetes (type 1 and 2), and gastrointestinal disorders such as ulcerative colitis and Crohn’s disease. Furthermore, it can reduce the severity of necrotizing enterocolitis (NEC) in preterm infants. Moreover, human milk oligosaccharides (HMOs) present in breast milk show an immunomodulatory, prebiotic, and neurodevelopmental effect that supports the microbiota–gut–brain axis. Material and methods: This study examined the state-of-the-art research, using keywords such as “breastfeeding”, “human milk oligosaccharides”, “microbiota–gut–brain axis”, “infants”, and “malnutrition”. The literature review was conducted by selecting articles between 2013 and 2024, as the most recent ones. The databases used were Web Science, PubMed, and Scopus. Results: We found multiple studies examining the composition of HM and infant formula (IF). However, further longitudinal studies and randomized control trials (RCTs) are needed to better understand the clinical outcomes that bioactive components exert on healthy and hospitalized children and how, in conditions of malnutrition, it is necessary to support the growth of the newborn. Conclusions: In this review, we affirm the importance of human milk and, through it, the modulation of the microbiota and the neuroprotective role in newborns, determining the health of the following years of life.

Year:

2024

Objective Cenobamate (CNB), a recently approved antiseizure medication by the European Medicines Agency (EMA), serves as an adjunctive therapy for focal‐onset seizures in adult patients unresponsive to at least two other treatments. Administered in polytherapy, CNB can potentially interact with co‐administered drugs in epilepsy patients, necessitating dose adjustments and the need for effective therapeutic drug monitoring (TDM). Methods In this study, we introduce a novel LC–MS/MS method for precise CNB quantification using Volumetric Absorptive Microsampling (VAMS), following validation according to ICH guidelines M10. VAMS samples are efficiently extracted with 200 μL of methanol, with chromatographic separation achieved using an Acquity UPLC HSS PFP column. The method's efficacy was confirmed through its application to real samples from adult CNB‐treated patients. Results Our results demonstrate that the method exhibits linearity within the range of 0.05–30 mg/L, with intra‐ and inter‐run precision ranging from 1% to 8% and accuracy from 1% to 10% based on 30 μL of sample. Furthermore, CNB stability in VAMS is confirmed for up to 15 days at 25°C and −20°C. Importantly, no significant difference was observed between CNB concentrations in VAMS samples and those in plasma obtained from venous blood. Significance This VAMS‐based LC–MS/MS method presents a robust alternative for TDM in CNB‐treated patients. Future investigations should explore CNB concentrations in capillary blood and assess their correlation with plasma levels to further enhance its clinical utility. Plain Language Summary Cenobamate is an antiepileptic drug and used for treatment of focal‐onset seizures in adult patients (≥18 age). TDM can prevent drug interactions and minimize drug toxicity. The aim of this work is to evaluate volumetric absorptive microsampling (VAMS) from capillary blood as an alternative strategy for TDM in patients treated with the newly antiepileptic drug. Our method is suitable for TDM, and this study suggests that VAMS allows monitoring of cenobamate concentration and can offer valuable support for personalized therapy in refractory epilepsy.

Year:

2024

Background: Human milk oligosaccharides (HMOs), which are unique bioactive components in human milk, are increasingly recognized for their multifaceted roles in infant health. A deeper understanding of the nexus between HMOs and the gut–brain axis can revolutionize neonatal nutrition and neurodevelopmental strategies. Methods: We performed a narrative review using PubMed, Embase, and Google Scholar to source relevant articles. The focus was on studies detailing the influence of HMOs on the gut and brain systems, especially in neonates. Articles were subsequently synthesized based on their exploration into the effects and mechanisms of HMOs on these interconnected systems. Results: HMOs significantly influence the neonatal gut–brain axis. Specific concentrations of HMO, measured 1 and 6 months after birth, would seem to agree with this hypothesis. HMOs are shown to influence gut microbiota composition and enhance neurotransmitter production, which are crucial for brain development. For instance, 2′-fucosyllactose has been demonstrated to support cognitive development by fostering beneficial gut bacteria that produce essential short-chain fatty acids. Conclusions: HMOs serve as crucial modulators of the neonatal gut–brain axis, underscoring their importance in infant nutrition and neurodevelopment. Their dual role in shaping the infant gut while influencing brain function presents them as potential game-changers in neonatal health strategies.

Year:

2024

Background Developmental and Epileptic Encephalopathies (DEEs) are defined by drug-resistant seizures and neurodevelopmental disorders. Over 50% of patients have a genetic cause. Studies have shown that patients with DEEs, regardless of genetic diagnosis, experience a central visual function disorder known as Cerebral (cortical) Visual Impairment (CVI). The prevalence of CVI in DEE patients is currently unknown. A quantitative synthesis of existing data on prevalence rates of this condition would aid in understanding the magnitude of the problem, outlining future research, and suggesting the need for therapeutic strategies for early identification and prevention of the disorder. Methods This systematic review and meta-analysis protocol adheres to the PRISMA-P statement and utilizes the JBI Manual for Evidence Synthesis, focusing on the prevalence of cerebral visual impairments in patients with developmental and epileptic encephalopathy. Eligibility criteria are established following the CoCoPop framework. Comprehensive database searches will include MEDLINE, EMBASE, Science Direct, Scopus, PsychINFO, Wiley, Highwire Press, and the Cochrane Library of Systematic Reviews. The risk of bias will be assessed using the JBI Critical Appraisal Checklist for Studies reporting prevalence data. Heterogeneity will be evaluated using Cochran’s Q statistic and the I2 statistic. Summary tables and narrative text will present characteristics of the included studies. Pooled prevalence estimates will be calculated using a random-effects model and presented graphically in forest plots. If heterogeneity is high, a narrative summary will be provided. The quality of evidence will be assessed using the GRADE methodology. Discussion This protocol outlines a systematic review and meta-analysis that aims to identify, collect, evaluate, and integrate epidemiological knowledge related to the prevalence of CVI in patients with DEEs. To the best of our knowledge, no other systematic review and meta-analysis has addressed this specific issue. The results will provide useful information for understanding the extent of the problem, outlining future research, and suggesting the need for early identification strategies. Systematic review registrations: This Systematic Review Protocol was registered in PROSPERO (CRD42023448910).

Year:

2024

Objective DYNC1H1 variants are involved on a disease spectrum from neuromuscular disorders to neurodevelopmental disorders. DYNC1H1 ‐related epilepsy has been reported in small cohorts. We dissect the electroclinical features of 34 patients harboring de novo DYNC1H1 pathogenic variants, identify subphenotypes on the DYNC1H1 ‐related epilepsy spectrum, and compare the genotype–phenotype correlations observed in our cohort with the literature. Methods Patients harboring de novo DYNC1H1 pathogenic variants were recruited through international collaborations. Clinical data were retrospectively collected. Latent class analysis was performed to identify subphenotypes. Multivariable binary logistic regression analysis was applied to investigate the association with DYNC1H1 protein domains. Results DYNC1H1 ‐related epilepsy presented with infantile epileptic spasms syndrome (IESS) in 17 subjects (50%), and in 25% of these individuals the epileptic phenotype evolved into Lennox–Gastaut syndrome (LGS). In 12 patients (35%), focal onset epilepsy was defined. In two patients, the epileptic phenotype consisted of generalized myoclonic epilepsy, with a progressive phenotype in one individual harboring a frameshift variant. In approximately 60% of our cohort, seizures were drug‐resistant. Malformations of cortical development were noticed in 79% of our patients, mostly on the lissencephaly–pachygyria spectrum, particularly with posterior predominance in a half of them. Midline and infratentorial abnormalities were additionally reported in 45% and 27% of subjects. We have identified three main classes of subphenotypes on the DYNC1H1 ‐related epilepsy spectrum. Significance We propose a classification in which pathogenic de novo DYNC1H1 variants feature drug‐resistant IESS in half of cases with potential evolution to LGS (Class 1), developmental and epileptic encephalopathy other than IESS and LGS (Class 2), or less severe focal or genetic generalized epilepsy including a progressive phenotype (Class 3). We observed an association between stalk domain variants and Class 1 phenotypes. The variants p.Arg309His and p.Arg1962His were common and associated with Class 1 subphenotype in our cohort. These findings may aid genetic counseling of patients with DYNC1H1‐ related epilepsy.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (61)

Niels K. Focke

-

GERMANY
View details

Federica Pigliasco

Istituto Giannina Gaslini

ITALY
View details

Christian Rummel

Professor AI Medical Systems

Deggendorf Institute of Technology

GERMANY
View details

Luis Concha

Professor

National Autonomous University of Mexico

View details

Benjamin Bender

University Hospital

GERMANY
View details

Rikke S. Møller

University of Southern Denmark

DENMARK
View details

Antonio Gambardella

Professor of Neurology

Università degli Studi Mediterranea di Reggio Calabria

ITALY
View details

Mariasavina Severino

IRCCS Istituto Giannina Gaslini

ITALY
View details

Justyna Paprocka

Medical University of Silesia

POLAND
View details

Terence O'Brien

MONASH UNIVERSITY

AUSTRALIA
View details

Clara Franziska Weber

Max Planck Institute for Human Cognitive and Brain Sciences

GERMANY
View details

Carlo Di Bonaventura

-

ITALY
View details

Julie Absil

Hôpital Erasme

BELGIUM
View details

Laura Canafoglia

MD, PhD

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY
View details

John S Duncan

University College London

UNITED KINGDOM
View details

Theodor Rüber

University Hospital Bonn

GERMANY
View details

Lorenzo Caciagli

PI

University of Pennsylvania

UNITED STATES
View details

Ezequiel Gleichgerrcht

Assistant Professor

Emory University

UNITED STATES
View details

Ziv Gan-Or

Montreal Neurological Institute and Hospital

CANADA
View details

Orrin Devinsky

Professor of Neurosurgery, Psychiatry, and Neurology

NYU School of Medicine

UNITED STATES
View details

Mark Philip Richardson

King’s College London

UNITED KINGDOM
View details

Matthias Kirschner

University of Geneva

SWITZERLAND
View details

Sara Larivière

Assistant Professor

Université de Sherbrooke

CANADA
View details

Gianpiero Cavalleri

Professor of Human Genetics

-

IRELAND
View details

Heath Pardoe

Associate Professor

MONASH UNIVERSITY

AUSTRALIA
View details

Casey Paquola

Young Investigator Group Leader

Forschungszentrum Jülich

GERMANY
View details

Patricia Desmond

head

University of Melbourne

AUSTRALIA
View details

Sanjay Sisodiya

University College London

UNITED KINGDOM
View details

Peter Taylor

UKRI Future Leaders Fellow / Professor

Newcastle University

UNITED KINGDOM
View details

Maria Eugenia Caligiuri

Professore Associato

-

ITALY
View details

Leonardo Bonilha

University of South Carolina

UNITED STATES
View details

Simon Keller

Chair

University of Liverpool

UNITED KINGDOM
View details

Allan Bayat

University of Southern Denmark

DENMARK
View details

Rhys Thomas

Reader in Epilepsy

Newcastle University Faculty of Medical Sciences

UNITED KINGDOM
View details

Patrick Kwan

-

AUSTRALIA
View details

Fernando Cendes

Full Professor

University of Campinas

BRAZIL
View details

Lucy Vivash

MONASH UNIVERSITY

AUSTRALIA
View details

Edward Boyd

Assistant Professor-Research

Michigan State University

UNITED STATES
View details

Birgit Frauscher

Professor

Duke University

UNITED STATES
View details

Colin Doherty

Prof.

Trinity College Dublin

IRELAND
View details

Stefano Meletti

Direttore

-

ITALY
View details

Emanuele Cerulli Irelli

Sapienza University of Rome

ITALY
View details

Eric Yu

McGill University

CANADA
View details

Vijay Tiwari

The Queen's University Belfast

UNITED KINGDOM
View details

Domenica Immacolata BATTAGLIA

Professore Associato (dal 2017)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

ITALY
View details

Gavin Winston

Professor of Neurology

Queen's University

CANADA
View details

Richard T. Ngomba

University of Lincoln

UNITED KINGDOM
View details

Alessia Cafaro

Health Researcher

Istituto Giannina Gaslini

ITALY
View details

Laura Licchetta

University of Bologna

ITALY
View details

Georgia Ramantani

Dozentin

University of Zurich

SWITZERLAND
View details

Dewi Schrader

Clinical Assistant Professor, Paediatric Neurologist

-

CANADA
View details

Clarissa Yasuda

Associate Professor

University of Campinas

BRAZIL
View details

Raffaele Falsaperla

Docenti di ruolo di IIa fascia

University of Ferrara

ITALY
View details

Martin Domin

Senior researcher

University Medicine Greifswald

GERMANY
View details

Boris C. Bernhardt

Associate Professor

McGill University

CANADA
View details

Anna Elisabetta Vaudano

University of Modena and Reggio Emilia

ITALY
View details

Angelo Labate

Full Professor of Neurology

University of Messina

ITALY
View details

Renzo Guerrini

AOU Meyer

ITALY
View details

Francesco Fortunato

Ricercatori a tempo determinato

Magna Graecia University

ITALY
View details

Marian Galovic

Head of Epilepsy Unit, Consultant Neurologist

University of Zurich

SWITZERLAND
View details

Antonietta Coppola

-

ITALY
View details